# Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

> **NCT04827953** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nelum Corp** · enrollment: 28 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel
- **DRUG:** NLM-001
- **DRUG:** Zalifrelimab

## Key facts

- **NCT ID:** NCT04827953
- **Lead sponsor:** Nelum Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-01
- **Primary completion:** 2025-04
- **Final completion:** 2025-04
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-12-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04827953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04827953, "Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04827953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*